Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 | Sep-30-20 |
| | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues: |
| Pharmaceutical distribution and specialty | 43,079.0 | 40,723.0 | 41,164.0 | 39,614.0 | 38,129.0 | 34,903.0 | 37,040.0 | 34,916.0 |
| Nuclear Precision Health Services | 258.0 | 234.0 | 211.0 | 208.0 | 215.0 | 201.0 | 196.0 | 196.0 |
| Pharmaceutical revenues | 43,337.0 | 40,957.0 | 41,375.0 | 39,822.0 | 38,344.0 | 35,104.0 | 37,236.0 | 35,112.0 |
| Revenue growth [+] | 13.0% | 16.7% | 11.1% | 13.4% | 15.4% | 0.0% | 4.3% | 5.0% |
| Pharmaceutical distribution and specialty | 13.0% | 16.7% | 11.1% | 13.5% | 15.3% | 0.0% | 4.3% | 5.1% |
| Nuclear Precision Health Services | 20.0% | 16.4% | 7.7% | 6.1% | 34.4% | -5.6% | -8.0% | -9.3% |
| EBIT | 451.0 | 487.0 | 426.0 | 406.0 | 358.0 | 511.0 | 413.0 | 402.0 |
| EBIT margin | 1.0% | 1.2% | 1.0% | 1.0% | 0.9% | 1.5% | 1.1% | 1.1% |
| |
| Capital expenditures | 79.0 | | | | 55.0 | | | |
| |
| Total assets | 26,409.0 | 25,470.0 | 24,427.0 | 23,955.0 | 23,624.0 | 23,078.0 | 23,567.0 | 22,809.0 |
| ROA | -8.4% | 19.4% | -0.1% | 1.2% | 1.5% | 0.6% | 2.6% | 0.7% |
| |
| Revenue Mix | 92.0% | 91.3% | 91.0% | 90.6% | 90.0% | 89.4% | 89.6% | 89.9% |
| EBIT Mix | 1252.8% | | | 97.8% | 221.0% | 108.0% | 89.6% | |
|